Stephanie Durham
Adult Health · Hominy, OKNPI 1306356183
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations.
Across 93 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$276
- Teva Pharmaceuticals USA, Inc.$237
- Johnson & Johnson$178
- Alkermes, Inc.$166
- Otsuka America Pharmaceutical, Inc.$148
- AbbVie$142
- plus $446 from 8 others
What the payments were for
- Food & beverage$1,593100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $276 |
| Teva Pharmaceuticals USA, Inc. | 13 | $237 |
| Johnson & Johnson | 17 | $178 |
| Alkermes, Inc. | 8 | $166 |
| Otsuka America Pharmaceutical, Inc. | 9 | $148 |
| AbbVie | 8 | $142 |
| Indivior Inc. | 6 | $102 |
| Lundbeck LLC | 4 | $87 |
| Neurocrine Biosciences, Inc. | 4 | $84 |
| E.r. Squibb & Sons, L.L.C. | 3 | $57 |
| Eisai Inc. | 2 | $43 |
| Sunovion Pharmaceuticals Inc. | 3 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
How this compares
$1,593 in reported general payments places this provider in the 70th percentile of 117 adult health providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 39 | $260,622 |
| Austedo XrDeutetrabenazine | 21 | $150,763 |
| Invega SustennaPaliperidone Palmitate | 48 | $143,188 |
| RexultiBrexpiprazole | 82 | $122,767 |
| LybalviOlanzapine/Samidorphan Malate | 42 | $65,545 |
| VraylarCariprazine Hcl | 38 | $55,776 |
| Abilify MaintenaAripiprazole | 14 | $35,084 |
| TrintellixVortioxetine Hydrobromide | 33 | $33,628 |
| CaplytaLumateperone Tosylate | 16 | $26,503 |
| LinzessLinaclotide | 18 | $15,061 |
| BelsomraSuvorexant | 20 | $9,196 |
| Clozapine | 56 | $8,756 |
| Lurasidone Hcl | 56 | $7,670 |
| Duloxetine Hcl | 227 | $5,529 |
| Aripiprazole | 117 | $5,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $237 | $411,38560 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $148 | $157,85196 claims |
| Johnson & JohnsonInvega Sustenna | $178 | $143,18848 claims |
| AbbVieVraylar, Linzess | $142 | $70,83656 claims |
| Alkermes, Inc.Lybalvi | $166 | $65,54542 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $276 | $26,50316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 117 adult health providers in Oklahoma.
Other adult health in Hominy
- Cynthia CattaneoOklahoma City$45K
- Melinda MackeyEl Reno$18K
- Miki ThompsonOklahoma City$14K
- Georgianne TokarchikTulsa$12K
- Kellie RohwerOklahoma City$11K
- Terry GreenOklahoma City$9K
- Nissy PhilipOklahoma City$8K
- Kelli AndersonTulsa$7K
- Deborah MewbourneTulsa$7K
- Terri HerrianNorman$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.